ClinicalTrials.gg
Active, not recruitingNCT06698471RESTOREUpdated May 2, 2025

Relief From Stress Via Social Protection in Senegal

An interventional study of Community worker training and Referral to Health System in Distress, Psychological, Depression - Major Depressive Disorder and Generalized Anxiety Disorder (GAD), sponsored by Georgetown University. Active, not recruiting at 1 site in Senegal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Georgetown University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
748
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Despite the growing prevalence of mental health disorders in low- and middle-income countries, significant barriers to seeking and accessing mental health services persist. Within lower income populations, the prevalence of mental health disorders and barriers to addressing them are worsened by poverty. Self-Help Plus is a group-based stress management program delivered using a task-sharing model and designed to circumvent barriers to addressing mental health concerns. Cultural adaptations of Self-Help Plus have been implemented in several countries and are considered cost-effective. However, to date, Self-Help Plus has not been adapted for Senegalese populations. The study detailed in this manuscript aims to assess the feasibility and acceptability of Self-Help Plus in lower income populations in Senegal.

The study is a pilot feasibility cluster-randomized control trial of Self-Help Plus in four Senegalese communities. Clusters of social protection program beneficiaries will be randomly selected to receive five sessions of Self-Help Plus. The intervention will be delivered in groups of up to 30 beneficiaries and co-facilitated by two community workers. A combination of quantitative and qualitative research methods will be used to assess the feasibility and acceptability of both the Self-Help Plus intervention and randomized control trial procedures. The study sample will include social protection program beneficiaries in the treatment and control groups, Self-Help Plus facilitators, project staff supporting the training of facilitators, and the intervention supervisor.

The findings of this study will be used to inform the potential integration of Self-Help Plus and/or similar mental health interventions into the national social protection program in Senegal.

Read the detailed description

The primary objective of the pilot feasibility cluster-randomized controlled trial is to assess the feasibility and acceptability of both the Self-Help Plus intervention and trial procedures through the collection of quantitative and qualitative data. The study will include two trial arms: (1) a control treatment-as-usual arm and (2) an intervention arm that will receive the adapted Self Help Plus intervention. The findings of the research detailed in this protocol may be used to inform the design of a potential larger randomized control trial powered to assess the effectiveness of Self-Help Plus in Senegalese populations. Additional secondary objectives of the pilot feasibility study are listed below.

  1. Assess feasibility of cluster randomization procedure to limit biases and risk of contamination;
  2. Determine recruitment and retention rates for Self-Help Plus sessions;
  3. Evaluate the feasibility and acceptability of intervention delivery by Self-Help Plus trained non-specialists;
  4. Assess the safety of an abbreviated training curriculum (during training, intervention delivery, and supervision);
  5. Assess feasibility and acceptability of outcome measures;
  6. Assess ethics and safety of trial procedures using the adverse event protocol;
02

Conditions studied

  • Distress, Psychological
  • Depression - Major Depressive Disorder
  • Generalized Anxiety Disorder (GAD)
03

In context

Generalized Anxiety Disorder

517 studies on the registry are indexed under Generalized Anxiety Disorder; 124 are open to participants now.

This study's enrollment of 748 is above the median of 83 across 439 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

Georgetown University is the lead sponsor of 292 studies on the registry; 40 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Community Worker facilitators of the intervention:
  • Patients: Enrolled in the World Bank Social Protection Programme

Exclusion criteria

Exclusion Criteria:

  • Community Worker facilitators of the intervention
  • Patients: Persons with a severe mental disorder or suicidality
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
748 participants (actual)

Study arms

  • Active comparator
    Treatment as usual

    Treatment as usual from Health System in Senegal

    Other: Referral to Health System

  • Experimental
    Relief from Stress via Social Protection in Senegal

    Training community workers in Self Help Plus intervention

    Other: Community worker training

Interventions

  • OtherCommunity worker training

    Training community workers in Self Help Plus intervention, a 5 session self-help intervention based on Acceptance and Commitment Therapy

  • OtherReferral to Health System

    Referral to Health System of Senegal

06

What researchers measure

Primary outcomes

  1. Engagement

    Of those who were offered the intervention, at least 25% attended one or more sessions.

    Time frame: From enrollment to the end of treatment at 5 weeks

  2. Retention

    At least 50% of the ever-attended beneficiaries attended at least any 4 intervention sessions

    Time frame: From enrollment to the end of treatment at 5 weeks

  3. Fidelity

    Fidelity to intervention elements at the level of 75% or greater according to the mean fidelity checklist for intervention elements across all sessions. Number of feasibility domains: n=15; higher is better, scored on 0-100%

    Time frame: From enrollment to the end of treatment at 5 weeks

Secondary outcomes

  1. General Health Questionnaire-12

    Brief psychological well-being scale. Score range: 0-36; Higher score indicates worse psychological well-being

    Time frame: Prior to initiation of treatment

  2. General Health Questionnaire-12

    Brief psychological well-being scale. Score range: 0-36; Higher score indicates worse psychological well-being

    Time frame: 2 months following initiation of treatment

  3. General Health Questionnaire-12

    Brief psychological well-being scale. Score range: 0-36; Higher score indicates worse psychological well-being

    Time frame: 5 months following initiation of treatment

  4. Patient Health Questionnaire-9

    Brief depression screening instrument. Score range: 0-27; Higher score indicates worse depressive symptoms

    Time frame: Prior to initiation of treatment

  5. Patient Health Questionnaire-9

    Brief depression screening instrument. Score range: 0-27; Higher score indicates worse depressive symptoms

    Time frame: 2 months following initiation of treatment

  6. Patient Health Questionnaire-9

    Brief depression screening instrument. Score range: 0-27; Higher score indicates worse depressive symptoms

    Time frame: 5 months following initiation of treatment

  7. Generalized Anxiety Disorder-7

    Brief anxiety screening instrument. Score range: 0-21; Higher score indicates worse anxiety symptoms

    Time frame: Prior to initiation of treatment

  8. Generalized Anxiety Disorder-7

    Brief anxiety screening instrument. Score range: 0-21; Higher score indicates worse anxiety symptoms

    Time frame: 2 months following initiation of treatment

  9. Generalized Anxiety Disorder-7

    Brief anxiety screening instrument. Score range: 0-21; Higher score indicates worse anxiety symptoms

    Time frame: 5 months following initiation of treatment

  10. Brief Resilience Scale

    Brief resilience measure. Score range: 0-30; Higher score indicates better resilience

    Time frame: Prior to initiation of treatment

  11. Brief Resilience Scale

    Brief resilience measure. Score range: 0-30; Higher score indicates better resilience

    Time frame: 2 months following initiation of treatment

  12. Brief Resilience Scale

    Brief resilience measure. Score range: 0-30; Higher score indicates better resilience

    Time frame: 5 months following initiation of treatment

  13. Acceptance and Action Questionnaire

    Brief scale of psychological flexibility. Score range: 0-35; Higher score indicates worse psychological flexibility

    Time frame: Prior to initiation of treatment

  14. Acceptance and Action Questionnaire

    Brief scale of psychological flexibility. Score range: 0-35; Higher score indicates worse psychological flexibility

    Time frame: 2 months following initiation of treatment

  15. Acceptance and Action Questionnaire

    Brief scale of psychological flexibility. Score range: 0-35; Higher score indicates worse psychological flexibility

    Time frame: 5 months following initiation of treatment

  16. Self Efficacy

    Brief scale of self efficacy. Score range: 0-24; Higher score indicates better self efficacy

    Time frame: Prior to initiation of treatment

  17. Self Efficacy

    Brief scale of self efficacy. Score range: 0-24; Higher score indicates better self efficacy

    Time frame: 2 months following initiation of treatment

  18. Self Efficacy

    Brief scale of self efficacy. Score range: 0-24; Higher score indicates better self efficacy

    Time frame: 5 months following initiation of treatment

  19. Locus of control questionnaire

    Brief scale measuring locus of control. Score range: 0-20; Higher score indicates better locus of control

    Time frame: Prior to initiation of treatment

  20. Locus of control questionnaire

    Brief scale measuring locus of control. Score range: 0-20; Higher score indicates better locus of control

    Time frame: 2 months following initiation of treatment

  21. Locus of control questionnaire

    Brief scale measuring locus of control. Score range: 0-20; Higher score indicates better locus of control

    Time frame: 5 months following initiation of treatment

Other outcomes

  1. Culture-specific measure of distress - Thinking too much

    Exploratory 1-item culture-specific measure of distress; Score range: 0-5; Higher score indicates worse psychological well-being

    Time frame: Prior to initiation of treatment

  2. Culture-specific measure of distress - Thinking too much

    Exploratory 1-item culture-specific measure of distress; Score range: 0-5; Higher score indicates worse psychological well-being

    Time frame: 2 months following initiation of treatment

  3. Culture-specific measure of distress - Thinking too much

    Exploratory 1-item culture-specific measure of distress; Score range: 0-5; Higher score indicates worse psychological well-being

    Time frame: 5 months following initiation of treatment

  4. Culture-specific measure of distress - Feelings that hurt the heart

    Exploratory 1-item culture-specific measure of distress; Score range: 0-5; Higher score indicates worse psychological well-being

    Time frame: Prior to initiation of treatment

  5. Culture-specific measure of distress - Feelings that hurt the heart

    Exploratory 1-item culture-specific measure of distress; Score range: 0-5; Higher score indicates worse psychological well-being

    Time frame: 2 months following initiation of treatment

  6. Culture-specific measure of distress - Feelings that hurt the heart

    Exploratory 1-item culture-specific measure of distress; Score range: 0-5; Higher score indicates worse psychological well-being

    Time frame: 5 months following initiation of treatment

  7. Culture-specific measure of well being - Heart has felt calm

    Exploratory 1-item culture-specific measure of well being; Score range: 0-3; Higher score indicates better well being

    Time frame: Prior to initiation of treatment

  8. Culture-specific measure of well being - Heart has felt calm

    Exploratory 1-item culture-specific measure of well being; Score range: 0-3; Higher score indicates better well being

    Time frame: 2 months following initiation of treatment

  9. Culture-specific measure of well being - Heart has felt calm

    Exploratory 1-item culture-specific measure of well being; Score range: 0-3; Higher score indicates better well being

    Time frame: 5 months following initiation of treatment

07

Study locations

1 site
  • Centre de Recherche Pour le Développement Economique et Social (CRDES)
    Dakar, Senegal
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06698471
Collaborators
World Bank, Centre de Recherche Pour le Développement Economique et Social (CRDES)
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Feb 24, 2025
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
May 2, 2025

Study contacts

Syed S Wahid, Doctor of Public Health
principal investigator · Georgetown University
Anne Hilger, PhD
principal investigator · World Bank

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion